Answers are grounded in this paper and cite their sources.
Background: Available evidence on biomarkers of acute mesenteric ischaemia (AMI) is limited due to unclear reporting of AMI mechanisms, localization and severity and random time points for biomarker sampling. The primary aim of this study was to identify a combination of biomarkers allowing accurate identification of transmural AMI, the primary determinant of outcome. Methods: In this prospective multicentre study, consecutive adult patients admitted with suspected AMI during one-year recruitment period were included before any AMI-directed intervention. Serial blood samples were collected during up to 72 hours from admission. Intestinal fatty acid-binding protein (iFABP), alpha-glutathione S-transferase (alpha- GST), ischaemia-modified albumin (IMA), D-lactate, signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1), lipopolysaccharide-binding protein (LBP), interleukin 6 (IL-6), procalcitonin, D-dimers, acid-base status, lactate, C-reactive protein (CRP), white blood cell count, creatinine and troponin were analysed. Biomarker accuracy was assessed by ROC analysis. Optimal biomarker combination was determined by exhaustive logistic regression modelling and cut-offs by multi-objective (Pareto) optimization. Internal validation was performed using bootstrap resampling. Results: Thirteen sites from six European countries included in total 256 patients, among them 86 without AMI, 158 with AMI and 12 with strangulating bowel obstruction identified only after study inclusion. No individual biomarker or biomarker combination accurately distinguished AMI from non-AMI. However, among patients with classical AMI (arterial occlusive, venous and non-occlusive mesenteric ischaemia [NOMI]), a combination of five biomarkers (IL-6, alpha-GST, CRP, Scube-1 and blood lactate) discriminated transmural (n=86) from non-transmural AMI (n=39) with AUC of 0.872 (0.802-0.942), positive likelihood ratio of 5.52 and negative likelihood ratio of 0.18. The presence of at least two of the following biomarkers above threshold values correctly classified 106/125 (85%) patients: IL-6 >130 ng/L, alpha-GST >2200 µg/L, CRP >180 mg/L, SCUBE-1 >22 µg/L, blood lactate >5.5 mmol/L. Conclusions: Although biomarkers could not reliably distinguish AMI from non-AMI in patients presenting with suspected disease, a five-biomarker panel identified transmural bowel injury with acceptable accuracy. These findings suggest that circulating biomarkers primarily reflect the extent of intestinal injury and necrosis rather than the presence of AMI itself, making them potentially valuable for identification of AMI patients with irreversible bowel damage requiring urgent intervention. Study registration: NCT06212921 (Registration Date 19–01-2024).
No takes yet. Share an insight, caveat, or question.
Blaser et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: